Dr. James Yarger, CEO of ENDECE Neural, will discuss the company’s novel therapeutic for directly inducing remyelination of demyelinated axons to treat neurological diseases such as Multiple Sclerosis (MS). Currently there are no drugs commerciallyavailableforremyelinationinMS,oranyotherdiseaseassociatedwith demyelination.ENDECENeuralmayhaveoneofthefirstcompoundswiththeability todirectlyinduceremyelination.Thisnewtherapeuticcouldpotentiallybeusedalone or in combination with other immunosuppressant or anti-inflammatory therapies to help restore function and mobility in MS patients.
